Free Trial Information
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...could include testing the combination of FACT inhibition and chemotherapy in additional models of SCLC. Cleveland BioLabs Inc....
...LLC have the oral FACT inhibitor CBL0137 in Phase I trials to treat solid tumors. Cleveland BioLabs...
Read More
BioCentury | Feb 8, 2016
Clinical News

Entolimod: Phase II started

...entolimod 5 days before surgery with or without a second injection 3 days before surgery. Cleveland BioLabs Inc....
Read More
BioCentury | Feb 1, 2016
Clinical News

CBLB612: Phase II started

...breast cancer patients. The study is supported by a development contract with the Russian government. Cleveland BioLabs Inc....
Read More
BioCentury | Nov 9, 2015
Financial News

Cleveland BioLabs withdraws follow-on

...Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-11-04 Type: Follow-on Underwriter: Ladenburg Thalmann Note: Cleveland BioLabs...
Read More
BioCentury | Jul 20, 2015
Clinical News

Protectan CBLB612: Phase I data

...led to dose-dependent increases in circulating absolute neutrophil counts that lasted for about 20 hours. Cleveland BioLabs Inc....
Read More
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

...that indirectly inhibit NF-κB in Phase I testing to treat non-small cell lung cancer (NSCLC). Cleveland BioLabs Inc....
Read More
BioCentury | Jul 13, 2015
Company News

Cleveland BioLabs, Bioprocess Capital Ventures deal

...for cancer. Bioprocess owns about a 53% stake in Incuron (see BioCentury, June 1, 2009). Cleveland BioLabs Inc....
Read More
BioCentury | Jun 29, 2015
Financial News

Cleveland BioLabs completes private placement

Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date completed: 2015-06-25 Type: Private placement Raised: $25 million Shares: 6.5 million Price: $3.87 Shares after offering: 10.5 million Investor: Accredited investor WIR Staff cancer...
Read More
BioCentury | May 6, 2015
Company News

Management tracks

...Oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI) named Langdon Miller president and CMO. Miller was VP of clinical research...
Read More
BioCentury | Apr 20, 2015
Financial News

Cleveland BioLabs Inc proposes follow-on

Cleveland BioLabs Inc . (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-04-10 Type: Follow-on To be raised: Up to $10 million Units: TBD Price prior: $3.67 Underwriter: Ladenburg Thalmann Note: The company is selling...
Read More
Items per page:
1 - 10 of 115
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...could include testing the combination of FACT inhibition and chemotherapy in additional models of SCLC. Cleveland BioLabs Inc....
...LLC have the oral FACT inhibitor CBL0137 in Phase I trials to treat solid tumors. Cleveland BioLabs...
Read More
BioCentury | Feb 8, 2016
Clinical News

Entolimod: Phase II started

...entolimod 5 days before surgery with or without a second injection 3 days before surgery. Cleveland BioLabs Inc....
Read More
BioCentury | Feb 1, 2016
Clinical News

CBLB612: Phase II started

...breast cancer patients. The study is supported by a development contract with the Russian government. Cleveland BioLabs Inc....
Read More
BioCentury | Nov 9, 2015
Financial News

Cleveland BioLabs withdraws follow-on

...Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-11-04 Type: Follow-on Underwriter: Ladenburg Thalmann Note: Cleveland BioLabs...
Read More
BioCentury | Jul 20, 2015
Clinical News

Protectan CBLB612: Phase I data

...led to dose-dependent increases in circulating absolute neutrophil counts that lasted for about 20 hours. Cleveland BioLabs Inc....
Read More
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

...that indirectly inhibit NF-κB in Phase I testing to treat non-small cell lung cancer (NSCLC). Cleveland BioLabs Inc....
Read More
BioCentury | Jul 13, 2015
Company News

Cleveland BioLabs, Bioprocess Capital Ventures deal

...for cancer. Bioprocess owns about a 53% stake in Incuron (see BioCentury, June 1, 2009). Cleveland BioLabs Inc....
Read More
BioCentury | Jun 29, 2015
Financial News

Cleveland BioLabs completes private placement

Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date completed: 2015-06-25 Type: Private placement Raised: $25 million Shares: 6.5 million Price: $3.87 Shares after offering: 10.5 million Investor: Accredited investor WIR Staff cancer...
Read More
BioCentury | May 6, 2015
Company News

Management tracks

...Oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI) named Langdon Miller president and CMO. Miller was VP of clinical research...
Read More
BioCentury | Apr 20, 2015
Financial News

Cleveland BioLabs Inc proposes follow-on

Cleveland BioLabs Inc . (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-04-10 Type: Follow-on To be raised: Up to $10 million Units: TBD Price prior: $3.67 Underwriter: Ladenburg Thalmann Note: The company is selling...
Read More
Items per page:
1 - 10 of 115